Targeting the DNA damage response in hematological malignancies

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Deregulation of DNA damage response (DDR) is key in cancer development.
• Targeting DDR pathways offers synthetic lethality, like PARP inhibitors in BRCA-mutated ovarian cancer.
• DDR inhibitors (DDRi) are emerging for hematological cancers, distinct from solid tumors.

Purpose of the Study:

• To review preclinical and clinical data of DDR inhibition in hematological malignancies.
• To identify hematological cancer subtypes responsive to DDR agents.
• To provide a framework for designing future clinical trials of DDR inhibitors.

Main Methods:

• Literature review of preclinical studies.
• Analysis of clinical trial data for DDR inhibitors in hematological cancers.
• Identification of combination strategies with chemotherapy and targeted agents.

Main Results:

• DDRi are under clinical development for hematological cancers.
• Certain hematological cancer subtypes show activity with DDR agents as single agents or in combination.
• High proliferative index in many hematological cancers supports targeting DDR and replicative stress.

Conclusions:

• DDR inhibitors represent a promising therapeutic strategy for hematological malignancies.
• Further research and clinical trials are needed to optimize DDRi use in specific blood cancer subtypes.
• Combinatorial approaches targeting DDR and replicative stress warrant investigation.